Nirogacestat
Nirogacestat is a pharmaceutical drug with 17 clinical trials. Currently 11 active trials ongoing. Historical success rate of 80.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
12
Early Stage
4
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
80.0%
4 of 5 finished
20.0%
1 ended early
11
trials recruiting
17
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
Clinical Trials (17)
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
Nirogacestat in Patients With Kaposi Sarcoma
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants
Nirogacestat in Ovarian Granulosa Cell Tumors
Study of Cryoablation and Nirogacestat for Desmoid Tumor
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
All 17 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 17